Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology
Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.
Fierce Biotech20h
Kaken agrees to $180M deal to develop Alumis' lead TYK2 inhibitor in Japan
Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...
BridgeBio Pharma (NASDAQ:BBIO) Given New $50.00 Price Target at JPMorgan Chase & Co.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target increased by equities researchers at JPMorgan Chase & ...
BridgeBio Pharma (NASDAQ:BBIO) Trading 8.9% Higher Following Analyst Upgrade
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) shot up 8.9% during trading on Monday after JPMorgan Chase & Co. raised their price target on the stock from $44.00 to $50.00. JPMorgan ...
Fintel on MSN19h
Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation
Fintel reports that on March 25, 2025, Stifel initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with a Buy recommendation. Analyst Price Forecast Suggests 114.68% Upside As of March 19, ...